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Aims The aim of this study is to evaluate the positive inotropic effect of urocortin (Ucn) and to
characterize its signalling pathways.
Methods and results Contractility was measured in ex vivo Langendorff-perfused hearts isolated from
Wistar rats. Isolated ventricular cardiomyocytes were used to analyse intracellular calcium ([Ca2þ]i)
transients evoked by electrical stimulation and L-type Ca2þ current by confocal microscopy and
whole-cell patch-clamping, respectively. The application of Ucn to perfused hearts induced progressive,
sustained, and potent inotropic and lusitropic effects that were dose-dependent with an EC50 of
approximately 8 nM. Ucn effects were independent of protein kinase A (PKA) activation but were
significantly reduced by protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) inhibitors
and by brefeldin A, an antagonist of guanine nucleotide exchange factor, suggested to be an inhibitor
of exchange protein activated by cAMP (Epac). These whole-organ effects were correlated with the
inotropic effects observed in isolated cells: Ucn increased ICaL density, [Ca
2þ]i transients, cell shortening
and Ca2þ content of sarcoplasmic reticulum.
Conclusion Our results show that Ucn evokes potent positive inotropic and lusitropic effects mediated,
at least in part, by an increase in ICaL and [Ca
2þ]i transient amplitude. These effects may involve the









Urocortin (Ucn) is a 40-amino acid vasoactive peptide which
belongs to the corticotropin-releasing factor (CRF) family.1
Originally identified in rat midbrain, it has been detected
in the heart, brain, vasculature, kidney, and digestive
system.1–3 Ucn plays important roles in the regulation of
the hypothalamic–pituitary–adrenal axis and in endocrine,
behavioural, and autonomic responses to stress.4,5 Recent
studies indicate that Ucn exerts effects beyond the hypotha-
lamo–pituitary–adrenal axis, directly upon cardiac, vascu-
lar, and vaso-humoral function in health and cardiac
disease.6,7 Different reports have demonstrated that Ucn
induces an increase in heart rate, cardiac output, and coron-
ary blood flow.8,9 Along with these effects on cardiac func-
tion, Ucn has also been shown to protect both cultured
cardiac cells and intact heart against the damaging effects
of ischaemia/reperfusion injury.10,11
Ucn effects on heart contractility could be mediated
through modulation of intracellular Ca2þ handling. In
cardiac myocytes, cellular contraction is initiated by the
transient elevation in [Ca2þ]i during the excitation–
contraction coupling: during an action potential, Ca2þ
influx induced by activation of voltage-dependent L-type
Ca2þ channels upon membrane depolarization triggers the
release of Ca2þ via intracellular Ca2þ release channels (rya-
nodine receptors) of sarcoplasmic reticulum (SR) through a
Ca2þ-induced Ca2þ release mechanism.12,13 Relaxation
follows a decrease in [Ca2þ]i mainly by the Ca
2þ uptake
into the SR through the SR Ca2þ ATPase (SERCA) and Ca2þ
extrusion through the Naþ/Ca2þ exchanger.12 However, it
is not clear whether Ucn cardiac actions involve ICa modu-
lation since both a decrease14 and an increase15 of ICa
have been reported. Moreover, the specific mechanisms
underlying cardiac actions have not yet been elucidated.
Three distinct peptides—Ucn-I, II, and III—have been
identified. They bind to two G protein-coupled CRF recep-
tors.16,17 CRF-R1 is localized almost exclusively in the
central nervous system;3 meanwhile CRF-R2 is present in
both brain and peripheral tissues.18 In the cardiovascular*
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system, CRF-R2 are found in high concentration in the
human left ventricle, intramyocardial blood vessels, and
medial layers of internal mammary arteries.4 Binding of
Ucn to CRF-R2 increases its affinity for the Gs protein
leading to the stimulation of cAMP production. Recently,
we unveiled an unexpected mechanism of Ucn-induced
relaxation on rat coronary artery, which involves cAMP/
PKA regulation of Ca2þ-independent phospholipase A2 and
store operated Ca2þ channels.19 Classically, cardiac effects
of cAMP were attributed to phosphorylation by cAMP-
dependent PKA, but recently a guanine nucleotide exchange
factor (GEF) also directly activated by cAMP, named
exchange protein activated by cyclic AMP (Epac) was ident-
ified20 and introduced as a new player in several
cAMP-regulated processes such as cell permeability,21 cardi-
omyocytes hypertrophy,22 and Ca2þ handling in cardiomyo-
cytes,23 in a PKA-independent manner. Recently, Epac
activation was proposed to activate MAPK (mitogen-
activated protein kinase) subfamily ERK1/2 (extracellular
signal-regulated kinases 1/2) in endothelial cells. Moreover,
CRF receptors in cardiomyocytes are known to couple with
signalling cascades other than the cAMP–PKA pathway. For
example, Ucn-dependent stimulation of PKCepsilon24 or
ERK11 has been reported.
In this study we aimed to get further insights into the sig-
nalling pathway that mediates Ucn-evoked inotropic effect
on rat heart, with special emphasis on cAMP, PKA, Epac,
PKC, and MAPK signalling pathways.
2. Methods
All the experiments were performed in accordance to the animal
care guidelines of the European Communities Council (86/609/
EEC). And this study conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996). All procedures
were approved by the Committee of Animal Research at the Univer-
sity of Seville.
2.1 Ex vivo Langendorff-perfused rat heart
Adult male Wistar rats weighing 250–450 g were heparinized (4 IU/g
i.p.) and anaesthetized by intraperitoneal administration of keta-
mine hydrochloric acid (1–2 mL/250 g). The hearts were quickly
removed, mounted on the aortic cannula of the Langendorff per-
fusion system apparatus, and perfused with an oxygenated Krebs–
Henseleit buffer (118 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2,
1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, and 5 mM glucose)
as described previously.25 The buffer was equilibrated with 95% O2
and 5% CO2. To obtain an isovolumetrically beating preparation, a
latex balloon filled with water and connected by a catheter to a
transducer (Abbott, IR), was inserted through the left atrium into
the left ventricle and inflated to provide an end-diastolic pressure
between 8 and 12 mmHg. Before each experimental protocol was
initiated, the isolated hearts were set at a mean arterial pressure
of 60–80 mmHg and were allowed to stabilize at 378C for 40–
60 min. Chart Powerlab software (ADInstruments) was used for con-
tinuous recording throughout the experiments of heart rate, left
ventricular pressure (LVP), and maximum positive and negative
derivative of left ventricular pressure (+dP/dt) as shown in
Figure 1. The heart contractility under different treatments was
evaluated by the analysis of þdP/dt, which corresponds to %
increase of þdP/dt normalized to basal þdP/dt after stabilization
period. Ucn was also studied in rate-paced hearts without any
significant change in the contractility when compared with
no-paced hearts.
2.2 Isolation of ventricular myocytes
The hearts were removed and mounted on a Langendorff-perfusion
apparatus. The ascending aorta was cannulated, and a retrograde
perfusion was set-up. The heart was first perfused for 2 min at
36–378C with a nominally calcium-free Tyrode solution containing
0.2 mM ethylene glycol tetraacetic acid (EGTA), and then for
10 min approximately with the same Tyrode solution containing col-
lagenase type II (Worthington) plus 1 mg/mL of bovine serum
albumin (BSA; Sigma), all in the presence of 50 mM CaCl2. After per-
fusion, the hearts were removed from the Langendorff apparatus
and the left and right ventricles were cut-off, chopped into small
pieces, and gently shaken for 3 min in a standard Tyrode solution con-
taining 0.5 mM of CaCl2 to disperse the isolated cells. Subsequently,
isolated cells were filtered, centrifuged, and suspended in the
Tyrode solution containing 1 mMCaCl2. All the experiments were per-
formed at room temperature (24–268C) on Ca2þ-tolerant rod-shaped
myocytes. The nominally calcium-free Tyrode solution for isolation of
myocytes contained (mM): 130 NaCl, 0.5 MgCl2, 5.4 KCl, 22 glucose,
25 HEPES, 0.4 NaH2PO4, 5 NAHCO3; pHwas adjusted to 7.4with NaOH.
2.3 Intracellular Ca21 measurement
[Ca2þ]i transients were recorded in freshly isolated cardiomyocytes
loaded with the fluorescent Ca2þ dye fluo-3AM as previously
described.26 Cells were incubated for 20–40 min in the presence
or absence of 100 nM Ucn. During experiments, cells were continu-
ously superfused with normal Tyrode (mM): 140 NaCl, 4 KCl, 1.1
MgCl2, 10 HEPES, 10 glucose, 1.8 CaCl2 (pH was adjusted to 7.4
with NaOH), as previously described.23 To evoke [Ca2þ]i transients,
cardiomyocytes were stimulated at 1 Hz by field stimulation using
two parallel platinum electrodes. SR Ca2þ load was estimated by
rapid caffeine application (10 mM) on isolated myocytes. Images
were obtained with confocal microscopy (Meta Zeiss LSM 510, objec-
tive W.I. 63X and N.A. 1.2) by scanning the cell with an Argon laser
every 1.54 ms. Fluorescence was excited at 488 nm, and emission
was collected at .505 nm. The line of scan was selected parallel
to the longitudinal cell axis to measure cell shortening. Image analy-
sis was performed using IDL software (Research System Inc.). The
fluorescence values (F) were normalized by the basal fluorescence
(F0) to obtain the fluorescence ratio (F/F0), and decay time constant
(t) was calculated by fitting the descending phase of the fluor-
escence trace to a single exponential in each cell.
2.4 Electrophysiological studies
Cell membrane currents were recorded with the whole cell configur-
ation of the patch-clamp technique using an Axopatch-200B amplifier
controlled by a computer, which was equipped with pClamp (version
6.0-Axon Instruments) and interfaced to the amplifier with a Digidata
1322A (Axon Instruments). The recording pipettes filled with internal
solution had tip resistances ranging from 0.9 to 2 MV. Whole-cell
recordings were started 5 min after seal disruption, to allow cell
dialysis and stabilization of ICa.
27 ICaL was determined from a
holding potential of 250 mV, depolarizing pulses from 240 mV to
þ60 mV with 10 mV increments for 300 ms at a frequency of 0.2 Hz
were applied. The ICaL amplitude was measured as the difference
between peak current and the current at the end of the pulse. For
comparison between different cells, whole cell currents were
expressed as current densities that were calculated from the
current amplitude normalized by the membrane capacitance (Cm),
which was determined by applying +10 mV voltage steps from
260 mV and Cm was calculated according to the equation:
Cm ¼ t I0
DVmð1 I1=I0Þ
where t is the time constant, I0 the maximum capacitative
current value, Vm the amplitude of the voltage step, and I1 the
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amplitude of the steady-state current. The I–V relationships
obtained in the isolated cardiomyocytes under different conditions
were fitted with a function combining the Goldman–Hodgkin–Katz
equation.
Ca2þ recordings solution contained (mM): 140 NaCl, 1.1 MgCl2, 5.4
CsCl, 10 glucose, 5 HEPES, 1.8 CaCl2; pH was adjusted to 7.4 with
NaOH. The intracellular recording pipette solution contained (mM):
100 CsCl, 20 TEA, 5 EGTA, 10 HEPES, 5 Na2ATP, 0.4 Na2GTP, 5 Na2-
creatine phosphate, 0.06 CaCl2; pH was adjusted to 7.2 with CsOH.
2.5 PKA activity assay
The Kinase-Glow Luminescent Kinase Assay (Promega) was used to
measure the PKA activity in homogenates from perfused hearts
and isolated cardiomyocytes as described previously.19 The PKA
activity was measured in each sample according to the manufac-
turer’s instruction, and luminescence was recorded on a GloMaxTM
96 Microplate Luminometer (Promega). The activity is expressed
as RLU21 (relative light units)/amount of protein.
2.6 Drugs and statistical analysis
Drugs were purchased from Sigma, Promega, and Invitrogen. Group
data are presented as mean+ SEM. Single or paired Student’s t-test
was used to determine the statistical significance of the obtained
data. The significance between multiple groups was evaluated
using analysis of variance followed by Tukey test. Data marked
with asterisks (*) were considered significantly different.
3. Results
3.1 Urocortin evokes positive inotropic
and lusitropic effects
Acute effects of Ucn on LVP and contractility were analysed
in ex vivo-perfused heart. Figure 1A shows that Ucn (10 nM)
induced a strong increase in heart contractility indicated by
the enhancement of the positive and negative maximum
derivative of left ventricular pressure (+dP/dt). The com-
parison of superimposed LVP obtained right before Ucn
application and after 25 min in the presence of Ucn,
revealed that the peptide decreased the time-to-peak of
LVP, increased its amplitude, and accelerated its relaxation
(Figure 1B). In the presence of Ucn, þdP/dt increased
95.6+20.1% (n ¼ 9); meanwhile, it barely changed in
untreated hearts (þdP/dt ¼ 2.9+1.4%, n ¼ 8). The time
Figure 1 Effect of urocortin on contractility in ex vivo-isolated perfused rat hearts. (A) Representative original recording of the left ventricular pressure (LVP,
upper tracing), the heart rate (HR, middle tracing), and the derivative of left ventricular pressure (dP/dt, lower tracing) in Langendorff perfused heart before
(control) and after urocortin (Ucn, 10 nM) addition. (B) Superimposed traces of LVP from untreated (control) and urocortin-treated heart (Ucn, 10 nM). (C) Time-
course of the inotropic effect of urocortin (Ucn, 10 nM) on contractility. The summary data are mean+ SEM (n ¼ 8–9) from the urocortin (Ucn, 10 nM)-treated
and untreated hearts (control), and are expressed as a percent change vs. baseline values. (D) Dose-dependent effect of urocortin (Ucn, 1–100 nM) on þdP/dt in
perfused rat hearts. The fit was generated with Hill equation and the EC50 was approximately 8 nM (n ¼ 4). Data are significantly different at P , 0.05 when
indicated by asterisks.
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course of Ucn increased heart contractility was rather slow
and gradual; the augmentation of þdP/dt began within
5 min, peaked between 20 and 30 min, and was still signifi-
cantly high 40 min after Ucn application (Figure 1C). More-
over, the cumulative administration of Ucn (1–100 nM) to
isolated hearts showed a dose-dependent increase of þdP/
dt (Figure 1D). Maximal response to Ucn was observed at
100 nM, and the half-maximal effective concentration
(EC50) of Ucn was about 8 nM.
To further characterize the specificity of the effect of
Ucn, we tested whether b-adrenergic pathway was linked
to the positive inotropic effect. We applied isoproterenol
(ISO) to activate b-adrenergic receptors in hearts at the
time of maximum response to 100 nM Ucn. We observed
that 1 mM of ISO produced an additional rapid increase in
heart contractility (Figure 2A). Furthermore, in the pres-
ence of propranolol, the widely used inhibitor of
b-adrenergic receptors,28 Ucn increased þdP/dt to practi-
cally the same level as in untreated heart (Figure 2B). The
further addition of ISO (1 mM) failed to produce any increase
of heart contractility as shown in Figure 2B. All together
suggests that Ucn exerts strong positive inotropic effect
independent of the b-adrenergic pathway.
3.2 Ucn increases heart contractility independently
of PKA and seems to involve Epac pathway
Ucn binds with high affinity to the CRF-R2, which couples to
Gs/cAMP/PKA signalling.2,18 Therefore, we examined
whether Ucn action is mediated by the activation of PKA.
We assayed the activity of PKA in perfused hearts and in iso-
lated cardiomyocytes treated 10 min with Ucn (10 nM).
Figure 3A shows that indeed Ucn increased PKA activity
significantly in isolated perfused hearts. Heart pretreatment
with H89 (1 mM), a widely used inhibitor of PKA,15 signifi-
cantly reduced Ucn activation of PKA. In addition,
Figure 3B shows that PKA activation was also observed in iso-
lated cardiomyocytes treated with Ucn (10 nM), which was
largely inhibited by H89 (1 mM) and by astressin (0.5 mM),
specific antagonist of CRF-R2.29 However, in ex vivo-
perfused hearts, the inhibition of PKA had little effect on
Ucn-increased contractility. We observed that the infusion
of H89 alone decreased heart contractility, and maximum
þdP/dt enhanced by Ucn in the presence of H89 reached
82.9+10.9% (n ¼ 4) that is not statistically different from
the maximum þdP/dt in Ucn-treated hearts (95.6+
20.1%, n ¼ 9) as shown in Figure 3C. Furthermore, the analy-
sis of superimposed LVP obtained from heart treated first
with H89 and then with Ucn, revealed that the peptide
increased LVP amplitude and accelerated its relaxation
(Figure 3D) independent of PKA inhibition. Taken together,
these data indicate that while Ucn is able to stimulate
PKA, Ucn-induced positive inotropism and lusitropism
appear to be independent of cAMP/PKA pathway, suggesting
that other cAMP-binding protein and subsequent signalling
pathway may mediate the effects of Ucn.
Recently, a GEF called Epac has been shown to be involved
in several cAMP-regulated processes in the heart.21–23
Although there is no specific Epac antagonist yet, the
small GEF antagonist brefeldin A (BFA) has been used to
effectively antagonize Epac action on synaptic transmission
at the crayfish neuromuscular junctions.30,31 So, we used
BFA to gain insights into the possible role of Epac in
Ucn-induced heart contractility. First, we observed that
BFA alone (20 mM) had no effect on hearts basal contracti-
lity. Meanwhile, 5 min pretreatments with BFA (20 mM)
before Ucn application largely inhibited the positive inotro-
pic effect. þdP/dt increase reached only 20.4+7.6% (n ¼
4) as shown in Figure 3E. These data indicate that a
PKA-independent and BFA-sensitive pathway is involved in
Ucn inotropic effect, which could be due, at least in part,
to Epac-dependent pathway activation.
3.3 Role of PKC and ERK1/2 in the positive inotropic
effect induced by Ucn
To assess the possible contribution of PKC to the positive ino-
tropic action of Ucn, we evaluated the effects of the broad
spectrum PKC inhibitor chelerythrine, and the specific PKC
inhibitor GF109203X28 in ex vivo-perfused hearts. Figure 4
shows that both chelerythrine (10 mM) and GF109203X
(8 nM) applied 5 min before Ucn significantly prevented
the increased contractility. Increase in þdP/dt were
33.7+2.7% (n ¼ 5) and 21.0+7.9% (n ¼ 5), respectively
(Figure 4A). The effect of GF109203X was more potent
than chelerythrine inhibition, and their infusion alone had
no influence on hearts contractility.
Activation of PKC leads to phosphorylation of various cel-
lular proteins including ERK1/2. To assess the contribution of
ERK1/2 into the positive inotropism induced by Ucn, we
tested PD98059, the specific inhibitor of ERK1/2,11 in per-
fused hearts. Figure 4B shows that Ucn failed to increase
the contractility in hearts pretreated 5 min with PD98059
(5 mM). The inhibitory effect was very strong, and þdP/dt
increased by Ucn in PD98059-treated hearts reached
only 13.9+9.6% (n ¼ 5) indicating the important role of
Figure 2 b-Adrenergic receptor activation in hearts treated with urocortin.
(A) Summary data of þdP/dt time-course from perfused hearts treated with
urocortin (Ucn, 100 nM). Isoproterenol (ISO, 1 mM) was added at the end as
indicated. (B) Same as in (A) but in heart pretreated with propranolol
(Prop, 1 mM). Data are from four different hearts.
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ERK1/2 in the positive inotropic effect induced by Ucn.
PD98059 alone had no effect on basal contractility of the
heart.
3.4 Urocortin evokes positive inotropic and
lusitropic effects at the cellular level
Since intracellular Ca2þ increase plays a critical role in heart
contraction, we examined whether Ucn inotropic actions
were because of an enhancement in intracellular Ca2þ
mobilization. We investigated the effect of Ucn on [Ca2þ]i
transients and cell contraction in isolated cardiomyocytes.
Figure 5A shows representative examples of line scan
images taken from a control cardiomyocyte (top) and a
Ucn-incubated cardiomyocyte (bottom) under field stimu-
lation. Ucn (100 nM) incubation for 20–40 min increased
the amplitude of the [Ca2þ]i transient (Figure 5B) and
accelerated its decay (Figure 5C). Furthermore, cellular
contraction measured as % of cell shortening was also
increased by Ucn incubation (Figure 5D). This increase in
[Ca2þ]i transient amplitude was not prevented by PKA inhi-
bition but was largely blocked by PKC inhibition (data not
shown). [Ca2þ]i transient amplitude depends on SR Ca
2þ
load, hence we next analysed whether Ucn could modify
SR Ca2þ content. After field-stimulating the cell to reach
the steady state, caffeine was applied to empty the SR
and estimate the SR Ca2þ content in a control cardiomyo-
cyte (top) and in the incubated one during 20–40 min in
the presence of 100 nM Ucn (bottom) as shown in
Figure 5E. The caffeine-evoked [Ca2þ]i transients were sig-
nificantly higher in cardiomyocytes incubated with Ucn
(Figure 5F). A rise in [Ca2þ]i transients and the subsequent
higher contraction may be explained by an increase in SR
Ca2þ load observed in cardiomyocytes incubated with Ucn.
Taken together, these results suggest that the Ucn inotropic
effects in the whole heart could be because of an increase in
[Ca2þ]i and cellular contraction.
Figure 3 Role of protein kinase A (PKA) and Epac in urocortin effect. (A) Bar graph showing the activity of PKA in untreated hearts (control); in hearts perfused
10 min with urocortin (10 nM, Ucn); and in hearts pre-incubated 5 min with H89 (1 mM) and then 10 min with urocortin (10 nM, þH89; n ¼ 9 samples from three
different hearts). (B) PKA activity in isolated cardiomyocytes in different conditions as in (A). þAst is for cells treated 5 min with astressin (500 nM) and then
10 min with urocortin (10 nM; n ¼ 8 samples from three separate cultures). (C) Shows the effect of PKA inhibition with H89 on urocortin-evoked contractility
(þH89). H89 (1 mM) was applied 5 min before the addition of urocortin (10 nM; n ¼ 4). (D) Superimposed traces of LVP from H89-treated heart before (H89,
1 mM) and after urocortin addition (H89þUcn, 10 nM). (E) Time-course of urocortin (10 nM) effect on þdP/dt in untreated hearts (Ucn) and in hearts pretreated
5 min with brefeldin A (þBFA, 20 mM) to inhibit Epac. The summary data are from four experiments. *P , 0.05.
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3.5 Urocortin activates L-type Ca21 channels
L-type Ca2þ current (ICaL) is the main trigger of [Ca
2þ]i tran-
sient.12 Hence, we investigated if Ucn effects in [Ca2þ]i
could be owing to modulation of the L-type Ca2þ current
(ICaL) by Ucn. Figure 6A shows representative recordings of
Ca2þ currents from two isolated voltage-clamped cardio-
myocytes. Depolarizing steps evoked an inward current
with maximal values near 210 mV, which was enhanced in
cardiomyocytes incubated with Ucn (100 nM) compared
with the magnitude of ICaL in untreated cardiomyocytes.
Figure 6B illustrates the mean current density voltage
relations of ICaL (I/V ) recorded in non-treated (open
circles; n ¼ 15) and Ucn-treated isolated cardiomyocytes
(closed circles; n ¼ 10). The maximal ICaL density at
210 mV was 211.1+0.7 pA/pF in control and 218.1+
2.4 pA/pF (P , 0.01) in Ucn-treated cells. Moreover, ICaL
increase was prevented in cardiomyocytes pretreated with
the specific CRF-R2 receptor antagonist (astressin, 0.5 mM)
as represented in Figure 6C. Thus, Ucn significantly
increased ICa through a mechanism involving CRF-R2 in
cardiomyocytes.
4. Discussion
The present study provides new details unveiling the mech-
anism of the inotropic action induced by Ucn in the isolated
ex vivo Langendorff-perfused rat hearts. We showed that
Ucn exerts potent and gradual positive inotropic and lusitro-
pic effects, which reach maximum level at 20–30 min after
Ucn addition. Ucn-evoked inotropic response clearly dif-
fered from the classical b-adrenergic effect known to
develop usually rapidly. Indeed, we have demonstrated
that Ucn modulates the inotropic responsiveness of the
heart through different signalling pathway than the
b-adrenergic pathway. Ucn was active at the nanomolar
range and its effect was dose-dependent with an EC50
value of about 8 nM; thus Ucn appears to be among the
most potent endogenous positive inotropic substances.
Ucn binds with high affinity to the CRF-R2,2,18 whose acti-
vation leads to an increase in cAMP and consequent PKA acti-
vation. In fact, we showed that Ucn increases PKA activity
both in perfused hearts and in isolated cardiomyocytes.
And we confirmed that Ucn activation of PKA is mediated
by CRF-R2 in isolated cardiomyocytes. But PKA inhibition
had little effect on Ucn-induced positive inotropic effect,
which is not in accordance with the data reported in
rabbit cardiomyocytes. Ucn inotropic and lusitropic actions
involved PKA pathway, even though the inhibition of basal
activity of PKA in those cardiomyocytes was not shown.15
It is important to stand out that PKA inhibition by itself
decreased heart contractility confirming the critical role
played by PKA on heart basal activity as described pre-
viously.32 Our data clearly show that Ucn-exhibited positive
inotropism is mediated by a PKA-independent mechanism
suggesting that another cAMP-binding protein and sub-
sequent signalling pathway may be involved.
Recently, Epac has been involved in several cAMP-
dependent but PKA-independent cellular processes. So it is
likely that Epac may mediate Ucn effects. However, there
is not yet a specific Epac inhibitor. Nevertheless, the small
GEF-antagonist, BFA has been shown to be able to inhibit
Epac.30,31 BFA was originally used to interfere with vesicular
traffic from the Golgi apparatus by slowing GDP–GTP
exchange on ADP ribosylation factors (ARF); the latter are
targets of GEF for ARF that are structurally related to
Epac, although they are not activated by cAMP (for review
see Chardin and McCormick33). We showed that BFA did
not affect basal contractility of the heart but it did pre-
vented Ucn actions even with smaller concentration when
compared with that used in other studies.30,31 Thus, while
there is no specific inhibitor available of Epac, BFA seems
to be a useful tool to determine a possible implication of
Epac in the signalling pathway. Our results suggest a critical
role of a BFA-sensitive pathway, which seems to involve Epac
in Ucn-increased heart contractility. This finding is consist-
ent with the increasing numbers of reports that propose an
important role of Epac in heart, for example in Ca2þ hand-
ling in cardiomyocytes23 or cardiac excitation–contraction
coupling.34
Activation of PKC has been considered to be an important
pathway in cellular responses in cardiac myocytes,35 and its
implication in Ucn effects has been related especially to
heart protection against ischaemia.24,36 The effect of che-
lerythrine and GF109203X, non-specific and specific PKC
inhibitors, in Ucn-positive inotropic effects suggested a
role for the conventional isoforms of PKC. Activated PKC
can phosphorylate a wide spectrum of cellular proteins
such as MAPK. Indeed, classical and novel PKC have been
shown to stimulate MAPK in rat ventricular myocytes.37
Several reports have implicated the sub-family of MAPK,
ERK1/2 activation by Ucn as a survival pathway in cardiac
cells.11 Our data show for the first time that the inhibition
of ERK1/2 dramatically prevented Ucn effects suggesting a
critical role of ERK1/2 in the induced positive inotropism.
The contribution of MAPK to the positive inotropism is still
Figure 4 Urocortin-evoked positive inotropic effect involves Protein kinase
C and ERK1/2 activation. (A) Time-course of urocortin (10 nM) effect on
þdP/dt in hearts treated with urocortin (Ucn, 10 nM); in hearts pretreated
5 min either with chelerythrine (þChelerythrine, 10 mM); or GF109203X
(þGF109203X, 8 nM) to inhibit PKC, before the addition of urocortin
(10 nM; n ¼ 5 hearts). (B) Summary data of þdP/dt increase in hearts
treated with urocortin (Ucn, 10 nM); and in hearts pretreated 5 min with
PD98059 (þPD98059, 5 mM), to inhibit ERK1/2, before urocortin infusion
(n¼5). *P , 0.05.
E. Caldero´n-Sanchez et al.722





under debate although there are increasing reports that
demonstrated ERK1/2 implication in the heart
contractility.38–40
In addition, we confirmed that the inotropic effect of Ucn
could be mediated by an increase in Ca2þ handling, possible
consequence of the increased ICa.
41 We showed that Ucn
increased electrically evoked [Ca2þ]i transients in parallel
with the enhancement of SR Ca2þ contents, which provides
more Ca2þ to induce larger Ca2þ release from the SR. Ucn
acceleration of [Ca2þ]i transient decline may be involved
in the Ucn lusitropic effects. On the other hand, Ucn signifi-
cantly increased ICaL amplitude, which is the main trigger of
[Ca2þ]i transient and its amplitude marks the [Ca
2þ]i transi-
ents amplitude.12 ICaL potentiation required the activation
Figure 5 [Ca2þ]i transients, cell shortening, and sarcoplasmic reticulum Ca
2þ load were increased by urocortin in isolated cardiomyocytes. (A) Representative
examples of line-scan confocal images obtained in isolated myocytes field stimulated at 1 Hz in a control (top) and in a cardiomyocyte incubated during
20–40 min with urocortin (100 nM, bottom). (B) Amplitude of the fluorescence [Ca2þ]i transients (expressed as F/F0, where F is the peak fluorescence signal
and F0 the diastolic fluorescence), their decay time constants were obtained by fitting the decay trace to a single exponential (t, C), and the percentage of
cell shortening (D) in control cells (white bars) and in cells incubated with urocortin (orange bars); n ¼ 5–11; *P , 0.05; ***P , 0.001 with respect to control
cells. (E) Line-scan images obtained in a control (top) and in a urocortin incubated (bottom) cell showing intracellular [Ca2þ]i transients during field stimulation
at 1 Hz and SR Ca2þ release at caffeine (10 mM) application. Caffeine was applied at the moment indicated by the red arrow. (F) Bar graphs comparing the ampli-
tude of caffeine-evoked [Ca2þ]i transients in control cells (white bar) and cells incubated during 20–40 min with 100 nM urocortin (orange bar) expressed as F/F0.
n ¼ 7; **P , 0.01 with respect to control cells.
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of CRF-R2 as it was inhibited by astressin, which is not con-
sistent with a study in rat cardiomyocytes where Ucn was
proposed to decrease ICaL independently of CRF-R2 acti-
vation.14 There are very few studies of Ucn effects on ICa
in cardiomyocytes; thus, the mechanism of Ucn modulation
of L-type Ca2þ channel deserves further investigations.
In summary, we have demonstrated that the adminis-
tration of Ucn produced a progressive and long-lasting
potent positive inotropic effect in isolated rat heart.
These effects were mediated by cAMP through a
PKA-independent mechanism. We have shown for the first
time a BFA-sensitive pathway, suggesting a possible involve-
ment of Epac in Ucn actions. Moreover, we have demon-
strated the important role of PKC and ERK1/2 played in
Ucn-evoked positive inotropic effect. In addition, we have
shown a significant increase of ICaL, [Ca
2þ]i transients ampli-
tude, and SR Ca2þ content by Ucn, crucial events for the
evoked inotropic response. The beneficial action of the posi-
tive inotropic effects of Ucn together with the coronary
vasodilation in rat heart,19 may be useful in the treatment
of cardiovascular disorders, particularly heart failure,
nevertheless extensive clinical studies are needed to
warrant Ucn clinical significance.42
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